Study of Ultra‐Sensitive AMS Method to Identify Drug–Drug Interactions between Ciprofloxacin and Microdose 14C‐Caffeine
Abstract
Identifying drug–drug interactions, potentially affecting efficacy and safety of each drug is essential for drug development. Microdose, administration of a drug at less than 100 μg or 1/100 of its therapeutic dose, is a promising method to safely test drugs during development. This paper examines drug–drug interactions between therapeutic doses of ciprofloxacin and trace amounts of 14 C‐ caffeine for microdosing in mice using AMS for analysis. The pharmacokinetic (PK) parameters for caffeine with and without administration of ciprofloxacin did not show any change in T max . However, the values of T 1/2 , C max , and AUC inf with administration of ciprofloxacin increased by 57, 22, and 42%, respectively. This is in agreement with previous studies that used full prescription doses. It is shown here that microdose techniques combined with AMS measurements can be used for accurate prediction of drug–drug interactions while conducting relatively safe, small dose studies.
Related Papers
- → A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro(2008)198 cited
- → Physiologically based pharmacokinetic modeling of the drug drug interaction between rifampin and SGLT2 inhibitors: The contribution of CYP induction to the observed interaction(2018)1 cited
- → Study of Ultra‐Sensitive AMS Method to Identify Drug–Drug Interactions between Ciprofloxacin and Microdose 14C‐Caffeine(2018)
- → Pilot Study: Assessment of Drug-Food and Drug-Drug Interactions in the Outpatient Settings(2020)
- → A Drug-Drug Interaction Study of Vadadustat Coadministered With Cyclosporine, a P-gp Inhibitor, and Digoxin, a P-gp Substrate(2021)